2024: A year in Review Big Pharma & Academia Driving Autoimmune Disease Advancements

In 2024, research on autoimmune diseases revolutionized treatment approaches. Leaders in pharma, biotech, and academia achieved breakthroughs that offer hope to millions, reshaping the understanding and management of these complex conditions.

These highlights, presented by MD Bioproducts , reflect just a small fraction of the groundbreaking progress made by Big Pharma and Academia this year.

💊 Big Pharma Highlights (2024)

Big Pharma made advancements in biologics, oral therapies, and partnerships:

• Advances in Autoimmune Therapies:
- IL-23 inhibitors from Eli Lilly and Company's Mirikizumab and Johnson & Johnson's Guselkumab improve treatments for ulcerative colitis. Guselkumab addresses psoriatic arthritis; Crohn’s approval is pending.
- AstraZeneca's Anifrolumab, GSK's Benlysta, and Biogen’s partnership with UCB for Dapirolizumab Pegol offer options in lupus.
- UCB developed promising therapies for myasthenia gravis.
- Pfizer’s next-generation therapies for IBD are advancing.

• Biologics Leading the Way:
Dupixent (Regeneron / Sanofi), Stelara, Tremfya (Johnson & Johnson), and Cosentyx (Novartis) have redefined treatments for arthritis, psoriasis, and Crohn’s disease.

• Oral Therapies & Biosimilars:
Skyrizi and Rinvoq (AbbVie) are replacing Humira. Amgen has expanded biosimilar options to improve accessibility.

• Partnerships:
Roche acquired a TL1A antibody, while GSK, Eli Lilly, Bristol Myers Squibb, and AbbVie strengthened their autoimmune / immunology pipelines through biotech collaborations.


🧬 Academia Breakthroughs (2024)

Academia made transformative advancements in therapies, AI, and pathways:

• Innovative Therapies:
CAR-T Cell therapy successfully led to lupus remission in a patient study at the FAU Erlangen-Nürnberg, and ETH Zürich developed a bioelectronic implant for ankylosing spondylitis.

• AI & Biomarkers:
Trinity College Dublin used AI and extensive data to identify patterns in rare autoimmune diseases, improving its understanding of disease progression. In contrast, The Johns Hopkins University has progressed precision biomarkers for skin conditions.

• New Pathways:
Emory University identified a new family of enzymes that alleviate IgG-mediated diseases, Kyoto University pioneered peptide therapy to restore immune tolerance, and Mayo Clinic advanced autoimmune hepatitis treatments.


🔮 Looking Ahead to 2025

• Expanding CAR-T Cell & Treg Cell-based therapies to additional autoimmune conditions.
• Advancing biologics, nanomedicine, & combination therapies.
• AI-driven precision medicine & improved diagnostics.
• Innovations in microbiome, CRISPR, & regenerative approaches.
• Accelerating drug development through biotech collaborations.


MD Bioproducts empowers researchers worldwide with trusted tools to advance autoimmune discovery and push boundaries in science. With 30 years of expertise, it supports groundbreaking research.